Related Experiment Video

Updated: Jul 6, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
08:23

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

Hydroxyurea for children with sickle cell disease

Matthew M Heeney1, Russell E Ware

  • 1Harvard Medical School, Boston, MA, USA. matthew.heeney@childrens.harvard.edu

Pediatric Clinics of North America
|April 3, 2008
PubMed

Insights

Hydroxyurea therapy shows promise for improving sickle cell disease (SCD) in children. While effective and safe for managing sickling and organ damage, its long-term risks require further study.

Area of Science:

  • Pediatric Hematology
  • Pharmacology
  • Genetic Blood Disorders

Background:

  • Sickle cell disease (SCD) is a serious inherited blood disorder affecting children.
  • Current treatments aim to manage symptoms and prevent complications.
  • Hydroxyurea is a key medication with known benefits in SCD management.

Purpose of the Study:

  • To evaluate the efficacy and safety of hydroxyurea in pediatric SCD.
  • To understand hydroxyurea's mechanisms in addressing SCD pathophysiology.
  • To highlight the underutilization of this effective therapy.

Main Methods:

  • Review of existing clinical data and therapeutic applications of hydroxyurea in pediatric SCD.
  • Analysis of hydroxyurea's pharmacologic actions on sickling and hemolysis.
  • Assessment of documented side effects and therapeutic window.

Main Results:

  • Hydroxyurea effectively targets key SCD pathways like sickling, vaso-occlusion, and hemolysis.
  • The drug is generally well-tolerated with a wide therapeutic window.
  • Limited data exist on its long-term organ protective effects and risks.

Conclusions:

  • Hydroxyurea is an effective, albeit underutilized, therapeutic option for children with SCD.
  • Further research, including ongoing clinical trials, is needed to fully define long-term risks and benefits.
  • Optimizing hydroxyurea use can significantly improve the clinical course of pediatric SCD.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...